Overview

A Trial to Study BAY1753011 in Patients With Congestive Heart Failure

Status:
Completed
Trial end date:
2021-05-21
Target enrollment:
Participant gender:
Summary
To assess the efficacy of 30 mg of BAY1753011, with or without furosemide, versus furosemide alone in patients with heart failure and objective evidence of congestion.
Phase:
Phase 2
Details
Lead Sponsor:
Bayer
Treatments:
Antidiuretic Hormone Receptor Antagonists
Furosemide